HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma

BMC Cancer

Katharina Anna Sterenczak⁴  Andre Eckardt³  Andreas Kampmann³  Saskia Willenbrock⁴  Nina Eberle⁴  Florian Länger⁵  Sven Kleinschmidt²  Marion Hewicker-Trautwein²  Hans Kreipe⁵  Ingo Nolte⁴  Hugo Murua Escobar¹  Nils Claudius Gellrich³ 

[1] Division of Medicine, Department of Haematology/Oncology, University of Rostock, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany

[2] Department of Pathology, University of Veterinary Medicine Hannover, Bünteweg 17, 30559 Hannover, Germany

[3] Department of Oral and Maxillofacial Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany

[4] Small Animal Clinic, University of Veterinary Medicine Hannover, Bünteweg 9, 30559 Hannover, Germany

[5] Institute for Pathology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany

关键词: Comparative oncology;    Dogs;    Animal model;    Lin28;    mir-98;    let-7;    HMGA2;    HMGA1;    Squamous cell carcinoma;   

Others  :  1121047
DOI  :  10.1186/1471-2407-14-694

 received in 2013-03-27, accepted in 2014-09-17,  发布年份 2014

【 摘 要 】

Background

Humans and dogs are affected by squamous cell carcinomas of the oral cavity (OSCC) in a considerably high frequency. The high mobility group A2 (HMGA2) protein was found to be highly expressed in human OSCC and its expression was suggested to act as a useful predictive and prognostic tool in clinical management of oral carcinomas. Herein the expression of HMGA2 and its sister gene HMGA1 were analysed within human and canine OSCC samples. Additionally, the HMGA negatively regulating miRNAs of the let-7 family as well as the let-7 regulating gene Lin28 were also comparatively analysed. Deregulations of either one of these members could affect the progression of human and canine OSCC.

Methods

Expression levels of HMGA1, HMGA2, Lin28, let-7a and mir-98 were analysed via relative qPCR in primary human and canine OSCC, thereof derived cell lines and non-neoplastic samples. Additionally, comparative HMGA2 protein expression was analysed by immunohistochemistry.

Results

In both species, a significant up-regulation of the HMGA2 gene was found within the neoplastic samples while HMGA1 expression did not show significant deregulations. Comparative analyses showed down-regulation of mir-98 in human samples and up-regulation of let-7a and mir-98 in canine neoplastic samples. HMGA2 immunostainings showed higher intensities within the invasive front of the tumours than in the centre of the tumour in both species.

Conclusions

HMGA2 could potentially serve as tumour marker in both species while HMGA1 might play a minor role in OSCC progression. Comparative studies indicate an inverse correlation of HMGA2 and mir-98 expression in human samples whereas in dogs no such characteristic could be found.

【 授权许可】

   
2014 Sterenczak et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Petersen PE: Oral cancer prevention and control–the approach of the World Health Organization. Oral Oncol 2009, 45(4–5):454-460.
• [2]Mannarini L, Kratochvil V, Calabrese L, Gomes Silva L, Morbini P, Betka J, Benazzo M: Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital 2009, 29(3):119-126.
• [3]Withrow S, Vail D: Withrow and MacEwen’s Small Animal Clinical Oncology. 4th edition. St. Louis: Saunders Elsevier; 2007.
• [4]Mallet Y, Avalos N, Le Ridant AM, Gangloff P, Moriniere S, Rame JP, Poissonnet G, Makeieff M, Cosmidis A, Babin E, Barry B, Fournier C: Head and neck cancer in young people: a series of 52 SCCs of the oral tongue in patients aged 35 years or less. Acta Otolaryngol 2009, 129(12):1503-1508.
• [5]Kokemueller H, Rana M, Rublack J, Eckardt A, Tavassol F, Schumann P, Lindhorst D, Ruecker M, Gellrich NC: The Hannover experience: surgical treatment of tongue cancer–a clinical retrospective evaluation over a 30 years period. Head Neck Oncol 2011, 3:27. BioMed Central Full Text
• [6]Nao EE, Dassonville O, Poissonnet G, Chamorey E, Pierre CS, Riss JC, Vincent N, Peyrade F, Benezery K, Chemaly L, Sudaka A, Marcy PY, Vallicioni J, Demard F, Santini J, Bozec A: Ablative surgery and free flap reconstruction for elderly patients with oral or oropharyngeal cancer: oncologic and functional outcomes. Acta Otolaryngol 2011, 131(10):1104-1109.
• [7]Williams MD: Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol 2010, 4(1):62-69.
• [8]Cleynen I, Van de Ven WJ: The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008, 32(2):289-305.
• [9]Joetzke AE, Sterenczak KA, Eberle N, Wagner S, Soller JT, Nolte I, Bullerdiek J, Murua Escobar H, Simon D: Expression of the high mobility group A1 (HMGA1) and A2 (HMGA2) genes in canine lymphoma: analysis of 23 cases and comparison to control cases. Vet Comp Oncol 2010, 8(2):87-95.
• [10]Winkler S, Murua Escobar H, Meyer B, Simon D, Eberle N, Baumgartner W, Loeschke S, Nolte I, Bullerdiek J: HMGA2 expression in a canine model of prostate cancer. Cancer Genet Cytogenet 2007, 177(2):98-102.
• [11]Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004, 64(6):2024-2029.
• [12]Rho YS, Lim YC, Park IS, Kim JH, Ahn HY, Cho SJ, Shin HS: High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol 2007, 127(1):76-81.
• [13]Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007, 6:5. BioMed Central Full Text
• [14]Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y: Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol 2010, 41(4):493-502.
• [15]Rahman MM, Qian ZR, Wang EL, Sultana R, Kudo E, Nakasono M, Hayashi T, Kakiuchi S, Sano T: Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer 2009, 100(3):501-510.
• [16]Heo I, Joo C, Cho J, Ha M, Han J, Kim VN: Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 2008, 32(2):276-284.
• [17]Newman MA, Thomson JM, Hammond SM: Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008, 14(8):1539-1549.
• [18]Viswanathan SR, Daley GQ, Gregory RI: Selective blockade of microRNA processing by Lin28. Science 2008, 320(5872):97-100.
• [19]Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008, 14(9):400-409.
• [20]Ji J, Wang XW: A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis. J Hepatol 2010, 53(5):974-975.
• [21]Wu T, Jia J, Xiong X, He H, Bu L, Zhao Z, Huang C, Zhang W: Increased expression of Lin28B associates with poor prognosis in patients with oral squamous cell carcinoma. PLoS One 2013, 8(12):e83869.
• [22]Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S, Junghanss C, Nolte I, Bullerdiek J, Simon D, Murua Escobar H: High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res 2010, 30(12):5043-5048.
• [23]Adams JC: Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 1992, 40(10):1457-1463.
• [24]Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30(9):e36.
• [25]Chang JY, Wright JM, Svoboda KK: Signal transduction pathways involved in epithelial-mesenchymal transition in oral cancer compared with other cancers. Cells Tissues Organs 2007, 185(1–3):40-47.
• [26]Imai K: Epitehlial-mesenchymal transition and progression of oral carcinomas. Cancer Therapy 2004, 2:6.
• [27]Hammond SM, Sharpless NE: HMGA2, microRNAs, and stem cell aging. Cell 2008, 135(6):1013-1016.
• [28]Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou MY, Chu PY, Lo WL: MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol 2011, 47(3):202-210.
• [29]Liu Q, Lv GD, Qin X, Gen YH, Zheng ST, Liu T, Lu XM: Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep 2012, 39(2):1239-1246.
• [30]Bianchini L, Saada E, Gjernes E, Marty M, Haudebourg J, Birtwisle-Peyrottes I, Keslair F, Chignon-Sicard B, Chamorey E, Pedeutour F: Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. Genes Chromosomes Cancer 2011, 50(6):442-455.